Sepsis Diagnostics in the Era of "Omics" Technologies.

Miroslav Průcha,Roman Zazula,Stefan Russwurm

doi:10.14712/23362936.2018.2

Abstract

Sepsis is a multifactorial clinical syndrome with an extremely dynamic clinical course and with high diverse clinical phenotype. Early diagnosis is crucial for the final clinical outcome. Previous studies have not identified a biomarker for the diagnosis of sepsis which would have sufficient sensitivity and specificity. Identification of the infectious agents or the use of molecular biology, next gene sequencing, has not brought significant benefit for the patient in terms of early diagnosis. Therefore, we are currently searching for biomarkers, through "omics" technologies with sufficient diagnostic specificity and sensitivity, able to predict the clinical course of the disease and the patient response to therapy. Current progress in the use of systems biology technologies brings us hope that by using big data from clinical trials such biomarkers will be found.

Highlights

When Friedrich Miescher published a work on nuclein in 1869, nobody was aware of where this development in the medical field would go in the 140 years (Dahm, 2010)
In 1953, Watson and Crick only needed one DIN4 page to publish their groundbreaking work on the discovery of DNA structure (Watson and Crick, 1953).This discovery heralded the explosion of new findings related to research into the relation between the genome and its effect on the development and course of diseases.The beginning of the 21st century saw an unprecedented development of systemic biology.This scientific field in biology uses knowledge in mathematics, biochemistry, chemistry and informatics to study complex interactions present in biological systems
Its expansion was made possible by the development of technology used for obtaining genomic and proteomic data and information technology (IT) development.These technologies provide us with new knowledge in medicine in terms of disease diagnosis and pathogenesis and therapy

Summary

Introduction

When Friedrich Miescher published a work on nuclein in 1869, nobody was aware of where this development in the medical field would go in the 140 years (Dahm, 2010). Its expansion was made possible by the development of technology used for obtaining genomic and proteomic data and information technology (IT) development.These technologies provide us with new knowledge in medicine in terms of disease diagnosis and pathogenesis and therapy. In Germany, it is the third most frequent cause of death in the German population and already the leading cost factor in German intensive care medicine with total costs of EUR 1.7 billion per year (Brunkhorst and Reinhart, 2005). It affects all age groups and it is the leading cause of morbidity and mortality in critically ill patients following intensive care unit (ICU) admission.

PRECISION MEDICINE

Findings

Conclusion